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Abstract
Current antidepressant treatments are inadequate for many individuals, and when they are effective, they require several
weeks of administration before a therapeutic effect can be observed. Improving the treatment of depression is challenging.
Recently, the two-pore domain potassium channel TREK-1 has been identified as a new target in depression, and its
antagonists might become effective antidepressants. In mice, deletion of the TREK-1 gene results in a depression-resistant
phenotype that mimics antidepressant treatments. Here, we validate in mice the antidepressant effects of spadin, a secreted
peptide derived from the propeptide generated by the maturation of the neurotensin receptor 3 (NTSR3/Sortilin) and acting
through TREK-1 inhibition. NTSR3/Sortilin interacted with the TREK-1 channel, as shown by immunoprecipitation of TREK-1
and NTSR3/Sortilin from COS-7 cells and cortical neurons co-expressing both proteins. TREK-1 and NTSR3/Sortilin were
colocalized in mouse cortical neurons. Spadin bound specifically to TREK-1 with an affinity of 10 nM. Electrophysiological
studies showed that spadin efficiently blocked the TREK-1 activity in COS-7 cells, cultured hippocampal pyramidal neurons,
and CA3 hippocampal neurons in brain slices. Spadin also induced in vivo an increase of the 5-HT neuron firing rate in the
Dorsal Raphe Nucleus. In five behavioral tests predicting an antidepressant response, spadin-treated mice showed a
resistance to depression as found in TREK-1 deficient mice. More importantly, an intravenous 4-d treatment with spadin not
only induced a strong antidepressant effect but also enhanced hippocampal phosphorylation of CREB protein and
neurogenesis, considered to be key markers of antidepressant action after chronic treatment with selective serotonin
reuptake inhibitors. This work also shows the development of a reliable method for dosing the propeptide in serum of mice
by using AlphaScreen technology. These findings point out spadin as a putative antidepressant of new generation with a
rapid onset of action. Spadin can be regarded as the first natural antidepressant peptide identified. It corresponds to a new
concept to address the treatment of depression.
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Introduction
Recently, mouse models of depression have highlighted the
putative role of the TREK-1 channel in the mechanisms of action
of antidepressants. Deletion of the TREK-1 gene (also called kcnk2)
results in a depression-resistant phenotype that mimics treatment
with antidepressants [1]. TREK-1-deficient mice (kcnk22/2)
display an increased efficiency of 5-HT neurotransmission, a
blunted corticosterone response to stress and an increased
neurogenesis induced by selective serotonin reuptake inhibitors
(SSRIs). The involvement of the TREK-1 protein in mood
regulation may be related to its two following specific properties:
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TREK-1 (1) is directly inhibited by SSRIs [1] and by activated
protein kinases A and C and (2) is potentially linked to G-protein–
coupled receptors like the 5-HT1A receptor [2,3], suggesting that
this channel may participate in a 5-HT1A receptor-dependent
negative feedback loop. More interestingly, the Star*D study has
identified an association between the existence of four genetic
variants (SNPs) in the TREK-1 locus and resistance to multiple
antidepressant classes [4]. All these findings indicate that (1)
genetic variations in TREK-1 may identify individuals at risk for
depression treatment resistance and (2) a search of selective
blockers of TREK-1, hitherto not available, might potentially lead
to a new generation of antidepressants.
Growing evidence indicates that trafficking and addressing as
well as functional properties of native ion channels depend on their
lipidic and proteic environments. K+ channels are known to
interact with partner proteins that are crucial for their regulation.
To date, the only identified partner proteins of TREK-1 channels
are the A-kinase anchoring protein AKAP150 [5] and the
microtubule-associated protein Mtap2 [6] that enhance TREK-1
channel surface expression and current densities. As a conse-
quence of both its role in the sorting of membrane proteins and of
a cerebral localization similar to that of TREK-1 [7,8], we
investigated the possible role of the neurotensin (NT) receptor 3
(NTSR3, also called gp95/sortilin) [9] in the regulation of the
channel function. NTSR3/Sortilin is a 95–100-kDa type-1
membrane protein, consisting of a large luminal domain, a single
transmembrane segment, and a short C-terminal cytoplasmic tail.
A large part of NTSR3/Sortilin is localized at the level of the
Golgi apparatus where the protein triggers intracellular functions
of trafficking. Indeed, the C-terminus of NTSR3/Sortilin interacts
with the VHS domain of the sorting protein GGA2 (Golgi-
localizing, g-adaptin ear homology domain, ADP-ribosylation
factor-binding protein) [10]. This interaction confers to NTSR3/
Sortilin the property to sort SAP (sphingolipid activator proteins)
to lyzosomes [11]. Depending on its cellular location, NTSR3/
Sortilin may also act as a receptor or a co-receptor and binds NT,
the precursor of the Nerve Growth Factor (proNGF), the receptor-
associated protein (RAP), the lipoprotein lipase, and the propep-
tide released from its precursor form. For example, this receptor is
essential to proNGF induction of neuronal cell death via a
complex formed with the p75NTR within the cell membrane [12].
In the rat brain, NTSR3/Sortilin as well as TREK-1 are highly
expressed in cerebral structures involved in the pathophysiology of
depression [13], such as prefrontal and cingulate cortice,
amygdala, hippocampus, nucleus accumbens, dorsal raphe, and
hypothalamus [7,8]. NTSR3/Sortilin is synthesized as a proform
(prosortilin) that, in late Golgi compartments, is converted to the
functional ligand-binding receptor by cleavage and release of a 44
residue N-terminal propeptide (Gln1-Arg44, propeptide) by furin
[14]. Propeptide binds to the mature receptor with a high affinity
(Kd,5 nM). Structure-function relationship studies have identi-
fied that the peptide Gln1-Arg28 was as efficient on the binding
activity as the entire propeptide Gln1-Arg44, whereas the affinity of
the peptide Gln1-Arg16 was very low [15]. Therefore, we designed
the peptide spadin by conserving the sequence 17–28 in which we
added the sequence 12–16 (APLRP) in order to maintain
conformational stress. This partial propeptide (Ala12-Arg28) was
tested for its potential effects on TREK-1 channel regulation and
for its validation as an antidepressant drug in five behavioral
models of depression.
Results
NTSR3/Sortilin and Spadin Interact with the TREK-1
Channel
In an attempt to detect a physical and functional interaction
between the NT receptor and the potassium channel, we first
performed an immunoprecipitation of TREK-1 and NTSR3/
Sortilin. Experiments were performed on either mouse cortical
neurons or COS-7 cells co-expressing both proteins. Each
antibody immunoprecipitated the tested partner, i.e. NTSR3/
Sortilin [8] precipitated with the TREK-1 antiserum (Figure 1A
left panel) [16] and TREK-1 with the anti-NTSR3/Sortilin
antibody (Figure 1A right panel), in both COS-7 cells and cortical
neurons. We also demonstrated that both endogenous proteins
were colocalized in mouse cortical neurons (Figure 1B). Then, we
investigated the influence of NTSR3/Sortilin expression on the
sorting of TREK-1 to the plasma membranes. The expression of
TREK-1 within the plasma membranes, measured either by
preparing purified plasma membranes or by using cell surface
biotinylation, was enhanced (by a factor 3 and 6, respectively)
when COS-7 cells were cotransfected with NTSR3/Sortilin
(Figure 1C), confirming the interaction between the two proteins,
at least during the channel sorting. This interaction between
TREK-1 and NTSR3/Sortilin led us to examine whether NT
and/or the partial NTSR3/Sortilin propeptide (i.e. spadin) were
able to act on TREK-1 channel activity. We first characterized the
affinity of spadin on C13NJ, a microglial cell line expressing only
NTSR3/Sortilin as a receptor for NT, and devoid of TREK-1
(unpublished data). Similarly to NT, spadin bound to NTSR3/
Sortilin by displacing the binding of 125I-NT with an affinity of
8 nM, identical to that previously found with the full length
propeptide (Figure 1D) [17]. Since NT plays a role on C13NJ
migration in a wound-healing assay and that the full length
propeptide antagonizes this effect [17], we tested in the same assay
the spadin effect on NT-induced cell migration. In serum free
medium containing 10 nM NT, the number of cells that migrated
corresponded to 35.1%62.3% of the number of migrating cells in
the presence of 10% fetal calf serum (FCS). In absence of
stimulation, only 4%61% of cells migrated. The 10 nM NT-
induced cell migration was totally abolished in the presence of
1 mM spadin and remained to the basal level (6.2%61.3%) (Figure
S1). This result confirms that spadin displays identical binding and
functional properties as those of the full length propeptide. Then,
Author Summary
Depression is the most common of psychiatric illnesses,
with prevalence estimates ranging from 5% to 20% within
the general population. The design of effective treatments
for this disorder is a challenging process, and the use of
antidepressants has an overall low clinical efficacy as full
remission only occurs in one-third of the patients.
Moreover, the time between initial treatment and bene-
ficial effects is relatively protracted. These limitations
confirm the need to find new biological targets and drugs
for the treatment of depression. We recently identified a
conserved mouse potassium channel protein called TREK-1
(KCNK2) as a new target for treating depression. Here, we
demonstrate that spadin, a natural peptide derived from a
propeptide released in blood, is able to block the TREK-1
channel activity and has an antidepressant effect in mouse
models of depression. We showed that spadin is an
efficient antidepressant in mice that acts much faster (4 d
versus several weeks) than fluoxetine, the most commonly
used antidepressant. Our results with spadin in mice
highlight the potential for novel and more efficacious
treatments for depression in humans.
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we performed competition experiments between 125I-labelled
spadin and unlabelled spadin, NT or the N-terminal fragment of
the full length propeptide Gln1-Arg16 on membrane homogenates
from COS-7 cells transfected or not with TREK-1. Figure 1E
shows that spadin bound specifically to TREK-1 with an affinity of
about 10 nM. This binding was selective since NT was unable to
displace the binding of 125I-spadin and the N-terminal fragment
Gln1-Arg16 bound to TREK-1 with a very low affinity (1 mM)
close to that reported with NTSR3/sortilin (Figure 1E) [15]. The
weak effect of the N-terminal fragment Gln1-Arg16 was confirmed
by electrophysiological recordings on TREK-1 transfected COS-7
cells (Figure S2). We also performed association kinetics of 125I-
labelled spadin on whole COS-7 cells expressing TREK-1 at
37uC. The radioactivity associated with cells reached a plateau
within 30 min. Removal of surface-bound radioactivity by acid-
NaCl wash revealed that about 80% of total 125I-labelled spadin
bound at this time was intracellular, indicating that spadin was
internalized with TREK-1 following interaction (Figure 1F). These
Figure 1. NTSR3/Sortilin and Spadin interact with the TREK-1 channel. (A) Immunoprecipitation of NTSR3/Sortilin with anti-TREK-1
antibodies (IP a-TREK-1) or of TREK-1 with anti-NTSR3/Sortilin antibodies (IP a-Sort) from transfected COS-7 cells or mouse cortical neurons.
Immunoprecipitated proteins were subjected to Western blots and revealed using anti-sortilin (WB: a-Sort) or anti-TREK-1 (WB: a-TREK-1). (B) Double
immunofluorescence labeling of TREK-1 (Green) and NTSR3/Sortilin (Red) in mouse cortical neurons. Nuclei were labeled using Dapi (Blue) and co-
localized proteins were visualized using merge images (arrows); scale bar, 10 mm. (C) Influence of NTSR3/Sortilin on the expression of TREK-1 at the
plasma membranes. COS-7 cells were transfected with TREK-1 in the absence or in the presence of NTSR3/Sortilin. Crude homogenates, purified
plasma membrane proteins, or cell surface biotinylated proteins were subjected to Western blot analysis and revealed using anti-TREK-1 antibodies.
(D) Competition between 125I-NT and unlabeled Spadin (closed circles) or NT (open circles) for binding to C13NJ cell homogenates. Each point
represents the mean of duplicate determinations from 3 independent experiments. (E) Competition between 125I-Spadin and unlabeled Spadin
(closed circles), NT (open circles) or N-terminal fragment Gln1-Arg 16 (Nterm1-16, open triangles) for binding to TREK-1 transfected COS-7 cell
homogenates. Each point represents the mean of duplicate determinations from 2 to 5 independent experiments. Note that non-transfected COS-7
cells were totally devoid of 125I-Spadin binding. (F) Association kinetics of 125I-Spadin binding to COS-7 cells transfected with TREK-1. At the indicated
times, cells were either washed twice with 500 ml of binding buffer (closed circles) or treated with 500 ml of acid-NaCl buffer for 2 min (open circles).
doi:10.1371/journal.pbio.1000355.g001
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data strongly suggest that NTSR3/Sortilin constitutes a sorting
partner of the TREK-1 channel. We hypothesized that when both
proteins reach the plasma membrane, the propeptide, which is
cleaved in the Golgi apparatus, can be released. Then, it may bind
to NTSR3/Sortilin and/or to TREK-1 for tuning the channel
activity, by blocking a part of the expressed channels, and by
promoting their internalization. However, for such a mechanism
to be functionally effective under in vivo physiological conditions,
the propeptide has to be released into the blood circulation. To
validate this possibility, we therefore developed the Alpha Screen
(Amplified Luminescent Proximity Homogenous Assay) technol-
ogy for dosing the propeptide or spadin in serum samples from
mice [18,19,20]. This method is a bead-based non-radioactive and
homogenous proximity assay used to measure the interaction
between biological binding partners (Figure 2A–B). The principle
of this technology relies on the use of a Donor bead and an
Acceptor bead that generate a light signal when brought into
proximity (,200 nm). Upon laser excitation at 680 nm, the
Donor beads, containing a photosensitizer, will generate short-
lived singlet oxygen that can diffuse only a short distance before
returning to the ground state. The Acceptor beads, containing
chemiluminescers and fluorophores, will emit an amplified light
signal measurable at 600 nm (Figure 2A). Using this approach, we
calculated seric propeptide concentrations of 5 groups of 6
littermate mice. Interestingly, the mean concentration values of
the 5 groups were very close to each other, with a value of about
10 nM (Figures 2C and S3). These data clearly indicated that the
propeptide is released into the blood circulation. On this basis, we
next investigated its effects, and by extension those of spadin as
well, on TREK-1 channel activity.
Effects of Spadin on the TREK-1 Channel Activity
As previously described [21], TREK-1 basal channel activity was
strongly and reversibly activated by arachidonic acid (aa, 10 mM),
which induced a typical TREK-1 background current, character-
ized by outward rectification reversed at the predicted value for
EK+. Using the whole-cell patch-clamp technique on TREK-1
transfected COS cells, we first assessed the ability of the full length
peptide to inhibit the TREK-1 channel activity. COS-7 cells were
chosen because they weakly express the NTSR3/Sortilin receptor
(unpublished data). Indeed, 500 nM of propeptide was able to block
41%65% (n= 4) of the aa stimulated TREK-1 current measured at
0 mV (Figure 3A). Then, we tested spadin in the same experimental
conditions. As expected [15], we found that spadin displayed a
better affinity than the propeptide, since 100 nM of spadin were
able to block 63%612% (n= 16) of the TREK-1 current stimulated
by aa (Figure 3B). A spadin dose-response experiment indicated an
IC50 value of 70.7 nM at 0 mV (Figure 3C).
In order to confirm the action of spadin on TREK-1, by using
brain slices we directly recorded hippocampal CA3 pyramidal
cells, a cellular network that endogenously expresses both TREK-
1 and NTSR3/Sortilin [7,8]. Figure 3D depicts the currents
obtained following a ramp of potential in a CA3 neuron in the
presence of a cocktail of K+ blockers that have no effect on
TREK-1 [21]. In 12 out of 28 recorded neurons, arachidonic acid
increased the amplitude of the remaining current by 23.3%64.8%
(n= 12). Spadin blocked 90.8%66.0% (n= 12) of this effect.
Interestingly, the peptide alone inhibited 14.9%65.6% (n= 8) of
the current recorded in the presence of potassium blockers
(unpublished data), as did fluoxetine (13.0%63.8%, n= 5)
(unpublished data). Even if an effect of spadin on cationic
channels cannot be totally excluded, the inhibitory effect of spadin
on arachidonic acid-induced current in CA3 neurons from wild-
type mice was totally absent in the same experimental conditions
in the kcnk22/2 mice (Figure 3E). This result clearly demonstrates
that the current blocked by spadin is supported by TREK-1
channel. The inhibitory effects of spadin on endogenous TREK-1
were also measured in cultured pyramidal neurons from
hippocampus (49.7% inhibition with 1 mM of spadin, Figure S4)
and in the non-neuronal bTC3 pancreatic cell line (36% inhibition
with 1 mM of spadin, Figure 3F) that endogenously express both
proteins (Mazella, personal communication).
Figure 2. AlphaScreen assays. (A) Principles of AlphaScreen technology. Donor and acceptor microbeads can be coated with target-specific
antibody, proteins, or secondary reagents (streptavidin, glutathione, nickel). A signal is produced when the AlphaScreen acceptor, A, and donor, D,
beads are brought into proximity by a molecular interaction occurring between the binding partners captured on the beads. Laser excitation at
680 nm causes ambient oxygen to be converted to the singlet state by photosynthesizers on the donor bead. These react with chemiluminescent
agents on the Acceptor bead only when the latter is in close proximity, emitting light at 520–620 nm. Here, we illustrate a competition protocol
between seric propeptide, PE, and interacting donor beads, D, coupled-biotinylated spadin (b-spadin) with antibodies anti-propeptide (anti-PE)
coupled on acceptor beads, A. (B) An example of competition curve obtained with one group (nu 1) of 6 mice (1.1 to 1.6) among 5 different groups
(other curves are presented in the Figure S1). Values obtained are compared to the standard curve. (C) Seric concentrations of the full length
propeptide calculated for the 5 groups from competition experiments as shown in (B).
doi:10.1371/journal.pbio.1000355.g002
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Figure 3. Effects of Spadin on the TREK-1 channel activity. (A–B) Whole-cell currents measured in COS-7 transfected cells in presence of
potassium blockers (K+ blockers, 10 mM tetraethyl ammonium (TEA), 3 mM 4-aminopyridine (4-AP), 50 nM charybdotoxin, 10 mM glibenclamide,
100 nM apamin). Cells were clamped at 280 mV and voltage changes were either applied by ramp from 2100 to 50 mV, 1 s in duration (A, B main
panel) or by 10mV steps from 2100 to 40 mV, 1.5 s in duration (B inset). Currents were recorded after TREK-1 activation by 10 mM arachidonic acid
(aa) and aa + propeptide (PE, 500 nM) (A) or aa + Spadin (100 nM) (B). Native currents were recorded in absence (Control) and in presence of spadin
Spadin, an Antidepressant Sortilin-Derived Peptide
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Effect of Spadin on the Dorsal Raphe Nucleus (DRN) 5-HT
Neurotransmission
Since we have previously demonstrated that the deletion of the
TREK-1 gene results in an increase of the 5-HT neuron firing rate
in the DRN [1], we tested the effect of spadin on the same
neurons. We performed unitary extracellular recordings of these 5-
HT neurons in anesthetized animals (see Text S1). We constituted
two groups of mice, which received via an i.p. injection either
spadin (1025 M in a 100 ml bolus) or its vehicle (distilled water).
Starting 30 min after the injection, 3 to 4 successive descents were
performed along the DRN, for a total of 4–8 cells recorded per
animal (examples are given in Figure 3G). For each neuron, the
discharge was monitored during 60 s. In vehicle-injected mice, we
found a value of 1.2660.27 Hz, whereas after administration of
spadin, the mean firing rate of DRN 5-HT neurons was
significantly elevated up to 3.160.7 Hz (Figure 3H) (one-way
ANOVA, F(1,36) = 4.4, p,0.05), corresponding to a +146%
increase. As shown in Figure 3G (right panel), several neurons
found in spadin-injected mice discharged at up to 3, 5, or even
6 Hz, whereas most of the frequencies found in the saline group
were in a normal range (1–1.7 Hz) (Figure 3G left panel). The
average 5-HT neuron firing activity in spadin-treated animals was
almost identical to that observed in kcnk22/2 mice (Figure 3H) [1].
Very similar results were obtained when spadin was i.p. injected in
rats (Figure S5A–B).
Taken together, these results indicate that TREK-1 and
NTSR3/Sortilin are not only associated within the plasma
membrane but that spadin interacts directly with TREK-1 to
functionally inhibit its activity. These results prompted us to test
thereafter the antidepressant-like effects of spadin in behavioral,
morphological, and molecular models.
Acute, Subchronic, and Chronic Spadin Treatments
Induce Antidepressant Effects
We used five behavioral tests predicting an antidepressant
response (FST, TST, CMST, LH, and NSF) (see Text S1) similar
to these used in our previous work on the depression-resistant
phenotype of TREK-1 deficient mice [1]. Spadin efficacy was first
assessed in the Forced Swimming Test (FST) [22], which is a
highly reliable predictor for antidepressant potential [13]. Spadin
was administered 30 min before the test by intracerebroventri-
cular (i.c.v.), intravenous (i.v.), or intraperitoneal (i.p.) route at
doses of 1024 to 1028 M. Its effects were compared to the
behavior observed in kcnk22/2mice and in wild-type mice treated
with the efficient SSRI fluoxetine (i.p., 3 mg/kg). When placed in
an inescapable cylinder of water, spadin-treated mice exhibited
reduced floating or immobility times in the three modes of
injection with respect to their saline-treated counterparts
(Figure 4A). The immobility is interpreted as ‘‘a state of despair,’’
in that the animal is believed to have lost its motivation for escape-
oriented behaviors. The dose-responses of spadin showed that the
highest reduced immobility times (p,0.001) were observed at the
dose of 1027 M in i.c.v. (66.8%), 1026 M in i.v. (62.9%), and
1025 M in i.p. (55.30%) administration. The magnitude of the
antidepressant behavior was similar to that observed in fluoxe-
tine-treated wild-type and saline-injected kcnk22/2 mice. Then,
we determined the effect of an acute i.v. spadin administration
(1026 M) in the Tail Suspension Test (TST, Figure 4B), which is
often used to predict antidepressant efficacy [23,24], and in the
test of Conditioned Suppression of Motility (CMST, Figure 4C),
sensitive to antidepressants but not to anxiolytic drugs [25]. In the
TST, injection of spadin in wild-type mice 30 min before the test
significantly reduced immobility times when compared to saline-
treated wild-type mice (p,0.001). The antidepressant effect was
not statistically different to that observed in fluoxetine-injected
mice or kcnk22/2 mutants (p.0.05; Figure 4B). In the CMST,
shocked mice treated with saline displayed a marked suppression
of motility (CS, conditioned suppression; 9.1% of the saline non-
shocked group) when they were returned to the cage in which they
had previously received electric shocks (Figure 4C). Similarly to
what was observed in saline-treated kcnk22/2 mice, the admin-
istration of spadin (i.v., 1026 M) significantly reduced (by 84.4%)
the CS of motility without increasing motility in the correspond-
ing non-shocked group (Figure 4C). In these three tests (FST,
TST, and CMST), the injection of spadin in kcnk22/2 mice (see
Text S1) did not induce any change (Figure 4A–C), indicating that
there was no additional effects of spadin in the absence of the
TREK-1 channel. The subsequent experiments were therefore
performed only in wild-type mice. We subjected mice to the
Learned Helplessness test (LH, Figure 4D–E), validated as a
sensitive model of depression [13,26]. Compared with non-
shocked mice (i.e. that had not been exposed to inescapable
shocks), learned helpless (shocked) mice treated with saline
showed a significant increase of escape latencies, when tested
for their escape performance abilities 1 d after exposure to
inescapable shocks (Figure 4D–E). However, an acute spadin
treatment (i.v., 1026 M) provoked significant reduced escape
latencies after training (25.4%) compared to saline-treated mice,
demonstrating a strong antidepressant effect. Because changes in
the motor activity induced by the different drugs used could
influence the results, the motor behavior was measured following
i.p. treatments. Neither spadin nor fluoxetine had any effect on
mouse locomotion analyzed in short- or long-time after the drug
injection (Figure S6).
Current antidepressants are clinically effective only after several
weeks of administration. They increase the efficacy of 5-HT
transmission at the postsynaptic levels [27,28], but the initial
elevation of 5-HT also induces the stimulation of inhibitory 5-
HT1A autoreceptors within the DRN, counteracting the facilita-
tion of 5-HT transmission related to terminal reuptake blockade
[28]. The existence of this presynaptic effect is believed to be
responsible for the 2 to 6 wk delay before the onset of the
antidepressant’s therapeutic action, as this period corresponds to
the time required for 5-HT1A autoreceptors to desensitize [28].
(Spadin 100 nM, B). Peptides were applied via the bath medium. (C) Dose-dependent spadin inhibition of TREK-1 currents, IC50 value at 0 mV is of
70.7 nM. Currents were measured in presence of 10 mM aa. (D–E) Native currents recorded in the presence of K+ blockers after stimulation by 10 mM
of aa on CA3 pyramidal neurons from hippocampus slices in wild-type mice (D) or in kcnk2 deficient mice (kcnk22/2) (E) in the presence or the
absence of spadin (1 mM). Currents were elicited by a ramp from 2100 mV to 50 mV. (F) Native currents on b-TC3 cell line in similar experimental
conditions as (D–E). (G–H) Effect of spadin on the firing rate of DRN 5-HT neurons. Spadin (1025 M in a 100 ml bolus) or its vehicle was i.p.
administered. Recordings started 30 min after the injection and were performed for a maximal duration of 210 min thereafter. (G) Main panel:
Samples of ‘‘descents’’ performed along the DRN, showing typical integrated firing rate histograms in a vehicle- (left panel) or in a spadin-treated
(right panel) animal. Each cluster represents the electrical activity of one neuron, each bar representing the average number of recorded action
potentials per 10 s. Insets, examples of action potential waveforms of 5-HT neurons. (H) 5-HT neuron firing activity, calculated on the basis of all the
cells recorded within the successive tracks performed along the DRN. Values at the bottom of each column indicate the total number of neurons
recorded (n = 4 mice in both groups).
doi:10.1371/journal.pbio.1000355.g003
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Based on these observations, it has been proposed that a direct
facilitation of 5-HT firing rate in the DRN should be a
requirement for a faster onset of antidepressant action [29].
Interestingly, we observed an increase in the firing activity of DRN
5-HT neurons (Figure 3G). Obviously, such results raise the
possibility that spadin could exert a rapid onset of action. Hence,
we tested the potential antidepressant effect of spadin administered
during 4 d (subchronic treatment) using both the FST and TST
tests. As shown in Figure 5A–B, a 4-d treatment with spadin (i.v.,
1026M) significantly reduced the time spent immobile by 43.2% in
FST (p,0.01) (Figure 5A) and by 28.1% in TST (Figure 5B). In
contrast, as previously observed [30], subchronic fluoxetine
treatment had no effect when compared with saline (p.0.05).
Both spadin and fluoxetine administered during 15 d (chronic
treatment) significantly reduced the time of immobility to a similar
extend (around 30%) in the FST paradigm (Figure 5C). This result
shows that the antidepressant effect of spadin reached a maximal
level after 4 d and maintained the same potency following long-
term administration (15 d). The Novelty Suppressed Feeding test
(NSF) is usually carried out for demonstrating antidepressant
efficacy after chronic but not acute treatment [31]. Mice treated
with spadin (i.v., 1026 M) for 4 d showed a significant decrease in
latency to feed relative to saline-injected animals (Figure 5D). As
previously described [30], a 4-d regimen with fluoxetine (i.p.,
3 mg/kg) had no effect in the same condition (Figure 5D). None of
the drugs tested produced a significant change in food consump-
tion when mice returned in their home cage immediately after the
test (unpublished data).
Figure 4. Acute antidepressant effects of Spadin. (A–E) Acute treatments: Spadin (1024 to 1028 M) or Fluoxetine (3 mg/kg) or Saline solutions
were injected 30 min before the test in wild-type and kcnk22/2 mice (A, B, C). (A) Forced Swimming Test (FST, n = 10 per group), spadin-treated mice
had a shorter time of immobility comparable to those obtained with kcnk22/2 or fluoxetine-treated mice, whatever the way of spadin administration:
intracerebroventricular (i.c.v., n= 14 per group) (one-way ANOVA, F3,55 = 79.53, ***p,0.001 versus saline-treated mice), intravenous (i.v., n = 8 per
group except for fluoxetine and kcnk22/2 groups, n = 6) (one-way ANOVA, F5,43 = 26.27, ***p,0.001 versus saline-treated mice) or intraperitoneal (i.p.,
n = 10 per group except for kcnk22/2, n = 5 ) (one-way ANOVA, F3,34 = 40.58, *p,0.05, ***p,0.001 versus saline-treated mice). (B) Tail Suspension Test
(TST, n = 15 for saline and spadin groups, and n= 9 for fluoxetine and kcnk22/2 groups), i.v. spadin-treated mice had a shorter immobility score
comparable to those obtained with kcnk22/2 or fluoxetine-treated mice (one-way ANOVA, F3,47 = 11.40, **p,0.01, ***p,0.001 versus saline-treated
mice). (C) Conditioned Motility Suppression Test (CMST, n = 10 per group). Two-way ANOVA showed significant effects of shocks (F1,62 = 254.1,
p,0.001), treatment (F3,62 = 3.87, p,0.01) and an interaction between these two factors (F3,62 = 8.83, p,0.001).
###p,0.01 versus non-shocked mice.
In the shocked groups, spadin treatment reversed the freezing state induced by the shock training in saline-treated mice (7867 versus 1462 counts,
respectively). This effect was stronger than those observed for kcnk22/2 or fluoxetine-treated mice (one-way ANOVA, F3,39 = 10,87, *p,0.05,
***p,0.001 versus saline-treated mice). Counts are the number of squares crossed plus the number of climbings. (D and E) Learned Helplessness test
(LH, n = 12 per group). Shocked spadin-treated mice showed shorter escape latencies than saline-treated mice. Two-way ANOVA showed significant
effect for treatment (F1,110 = 7.93, p=0.01) and for assay (F5,110 = 3.56, p= 0.005 , *p,0.05 in shocked groups). (D) Mean escape latencies 6 SEM
averaged in 6 blocks of 5 trials, and (E) mean overall latency 6 SEM to escape across trials 1–30 as a function of spadin treatment. Two-way ANOVA
(Shocks6Treatment) showed an interaction between these two factors (F1,44 = 6.9, p= 0.012).
##p=0.007 for non-shocked saline-treated mice versus
shocked saline-treated mice.
doi:10.1371/journal.pbio.1000355.g004
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To verify that the antidepressant effects of spadin were not
species-specific, we also tested its efficiency in rats, by using the
FST test. An acute spadin injection (i.p., 1025 M) 30 min before
the test significantly reduced immobility time when compared with
saline-treated rats (p,0.001). The antidepressant effect was not
statistically different to that obtained with fluoxetine (20 mg/kg)-
injected mice or kcnk22/2 mice (p.0.05; Figure S5C).
Acute Spadin Treatment Does Not Affect Anxiety-Related
Behaviors
Stress and anxiety disorders lead to profound suffering and
disability, which contributes to the development of depression in
humans and plays a role in the severity and the recurrence of the
disease [32]. The connection between stress, anxiety, and
depression is often associated with elevated cortisol levels in
depressed patients [33]. We have previously demonstrated that the
deletion of the TREK-1 gene results in a hypoactivity of the
hypothalamic-pituitary-adrenal (HPA) axis, known to be involved
in the control of stress [1]. Here, we tested whether spadin (i.p.
1025 M) reduced corticosterone levels 30 min after a 10 min tube
restraint, a paradigm known to activate the HPA axis [34].
Figure 6A shows that the increase in corticosterone levels induced
by stress were reduced by 79.5% and 59.1% in spadin- and
fluoxetine-treated mice with respect to saline-treated animals.
Thereafter, to study whether spadin affects anxiety-related
behaviors, we investigated its anxiolytic profile in the three mouse
models of anxiety (elevated plus-maze, light-dark exploration,
Figure 5. Subchronic and chronic antidepressant effects of
Spadin. Subchronic treatments: Spadin (1026 M), Fluoxetine (3 mg/
kg), or Saline solutions were i.v. injected in a 100 mL bolus once a day
for 4 successive d before the test. In chronic treatments, spadin
(1026 M) and fluoxetine (1 mg/kg) were i.v. injected in a 100 mL bolus
once a day for 15 successive d. For each test there were 8 animals per
group. (A) In FST (one-way ANOVA, F2,23 = 26.08, ***p,0.001) and (B)
TST (one-way ANOVA, F2,24 = 9.8, *p,0.05 versus saline-treated mice),
spadin induced similar behaviors than those obtained with the acute
treatment, whereas fluoxetine was without effect [30]. (C) In FST,
chronic treatment with spadin or fluoxetine significantly reduced the
time of immobility (one-way ANOVA, F2,26 = 25.08, ***p,0.001 versus
saline-treated mice). (D) NSF paradigm: at the end of the 4 d treatment,
animals were food deprived for 1 d and then measured for their latency
to feed. Spadin treatment significantly reduced the latency to feed
when compared to saline or fluoxetine treatments (t test, ***p,0.001
versus saline-treated mice). In all graphs, data are expressed as means
6 SEM.
doi:10.1371/journal.pbio.1000355.g005
Figure 6. Effect of Spadin on stress and anxiety behaviors. (A)
Decreased stress-induced serum levels of corticosterone in mice treated
with spadin. We compared serum corticosterone concentrations (ng/ml)
sampled in the morning in mice acutely treated with spadin (i.v,
1026 M), saline or fluoxetine (i.p., 3 mg/kg) 30 min after a 10 min tube
restraint (n = 10 per group). Data are expressed as increase of the ratio
corticosterone levels 30 min after stress over basal corticosterone levels
30 min before restraint (one-way ANOVA, F2,27 = 18.30, *p,0.05,
**p,0.01 versus saline-treated mice). (B) Effect of spadin (i.p, 1025 M)
and diazepam (i.p., 0.5 mg/kg) on time spent in the open arms (s) of the
elevated plus-maze (n = 10 per group, one-way ANOVA, F2,27 = 8.75,
**p,0.001 versus saline-treated mice). (C) Effect of spadin (i.p., 1025 M)
and diazepam (i.p., 0.5 mg/kg) on the total number of entries in the
aversive white side in the light/dark transition test (n = 10 per group,
one-way ANOVA, F2,53 = 7.65, ***p=0.001 versus saline-treated mice).
(D) Influence of spadin (i.p., 1025 M) and diazepam (i.p., 0.5 mg/kg) on
mouse performance in the staircase test. Data are presented as the ratio
of number of rearings over the number of ascended steps (n = 10 per
group, one-way ANOVA, F2,44 = 4.86, *p,0.05 versus saline-treated
mice). In the three tests, mice were injected with either spadin or
diazepam 30 min before the test. In all graphs, bars indicate SEM.
doi:10.1371/journal.pbio.1000355.g006
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staircase) (see Text S1) that are the most commonly used [35].
Their most important feature resides in the predictive validity to
detect anxiolytic potential. Avoidance behaviors are reduced by
treatments with clinically efficacious anxiolytics, mainly by the
benzodiazepine agonist class, including diazepam [36]. In the
elevated plus-maze test, compared to diazepam (i.p., 0.5 mg/kg),
which significantly reduced the time spent into the aversive open
arms of the test apparatus (*p,0.05), spadin (i.p., 1025M) had no
effect (p.0.05) versus saline-treated mice (Figure 6B). Similarly, in
the light/dark exploration test, spadin-treated mice did not make
more transitions from the dark to the light compartment than did
mice treated with saline (p.0.05). In contrast, diazepam
significantly induced an increase in the number of light/dark
transitions (*p,0.05) (Figure 6C). The staircase paradigm
combines step-climbing, which serves as an index of exploratory
and locomotor activity, and rearing, which serves as an indicator
of anxiety. Exposure to diazepam induced a significant reduction
in both rearing and step ascending behaviors, leading to a decrease
of the rearing/step numbers ratio (**p,0.01, Figure 6D). In
contrast, spadin had no effect as compared to saline-treated mice
(p.0.05). Together, these results demonstrate that spadin has no
anxiolytic activity, when compared with the well-known diazepam.
Since spadin exerted efficient effects after i.p. or i.v. adminis-
tration, we evaluated its ability to pass through the blood-brain
barrier. 125I-labelled spadin (1 nmol of spadin plus 26106 cpm
125I-spadin) was i.v. injected and animals were sacrificed 30 min
following injection. The brains were rapidly removed and
homogenized. The radioactivity recovered in the brain was acid-
extracted, quantified, and analyzed by HPLC. These experiments
indicated that 1/1,000 of spadin was recovered in the brain after
i.v. injection (unpublished data). Identical amounts of spadin were
recovered in the brain after i.p. injection under the same
experimental conditions. The concentration of spadin recovered
into the brain was estimated to stand around 10 nM, a
concentration that corresponds to the affinity of spadin for
TREK-1 and sufficient to be active on TREK-1 channel activity.
This value was also in the same range of the IC50 determined by
electrophysiological measurements (Figure 3C).
Effects of a 4-d Treatment with Spadin on CREB-
Phosphorylation and Hippocampal Neurogenesis
SSRIs and tricyclics are known to enhance neurogenesis in the
subgranular zone (SGZ) of the dentate gyrus, but only after 2 or
3 wk of a chronic treatment [31,37]. The concomitant increases of
both the transcription factor cAMP response element-binding
protein (CREB) and hippocampal neurogenesis in response to
chronic antidepressant treatment, but not to non-antidepressant
psychotic drugs, strongly suggest that CREB regulates hippocam-
pal neurogenesis [13,38]. We tested therefore whether spadin was
able to induce an increase in hippocampal neurogenesis and a
faster activation of CREB. We analyzed the neurogenesis in the
dentate gyrus of the mouse hippocampus, by counting the number
of progenitor cells that incorporate the DNA synthesis marker 5-
bromo-29deoxyuridine (BrdU) and that are differentiated into
mature neurons [31,37]. Interestingly, in the SGZ, a 4-d treatment
with spadin (i.p. 1025M) significantly increased by 2-fold the
number of BrdU-positive cells with respect to saline conditions
(Figure 7A–B). The neurogenic effect of spadin was maintained
after a long-term administration (15 d, Figure 7C). In contrast, a
4-d regimen with fluoxetine had no effect on neurogenesis, but
fluoxetine induced a significant increase in the number of BrdU-
positive cells when it was administered during 15 d (Figure 7C).
Dual labeling of BrdU and doublecortin (DCX), a specific marker
of neuronal precursors [39], revealed that 85.2% of BrdU-labeled
cells expressed DCX (Figure 7A right bottom panel, 7B). No
colocalization of BrdU-positive cells with the astroglial marker
GFAP (glial fibrillary acidic protein) was observed (Figure 7A left
bottom panel).
The next step was to determine whether the enhanced adult
spadin-induced neurogenesis was related to an increased hippo-
campal activation of CREB, as measured by its phosphorylation
into pCREB. Compared with saline-treated mice, a 4-d treatment
with spadin (i.p., 1025M) induced a large increase of pCREB
labeling, restricted to the specific SGZ region of mouse
hippocampal tissue sections (Figure 7D). The counting of pCREB+
cells revealed that the spadin administration during 4 d signifi-
cantly led to a 2-fold increase in the number of pCREB-labeled
neurons when compared with the saline group (p,0.001,
Figure 7E). Western blot analysis, which showed an immunore-
active band at 46 kDA corresponding to the phosphorylated active
form of CREB, confirmed that a 4-d treatment with spadin
(i.p.,1025 M) stimulated the hippocampal phosphorylation of
CREB, whereas the amount of total CREB remained unchanged
(Figure 7F). Quantification of blots indicated a significant 4-fold
stimulation of pCREB within the hippocampus extracts. To
examine the relationship between pCREB and neurogenesis,
expression of pCREB in newborn cells, visualized by DXC
labeling, was examined by immunofluorescence. Double labeling
for pCREB and DCX demonstrated a colocalization of pCREB
expression in several precursor neurons in the presence of spadin
(Figure 7G). These data pointed out that spadin induced a specific
and rapid onset of neurogenesis and CREB activation in adult
brain mice.
Discussion
This study identifies spadin as the first peptidic antagonist of the
TREK-1 channel and illustrates its potent antidepressant proper-
ties by using biochemical, electrophysiological, and behavioral
approaches. Spadin is a partial peptide derived from the
propeptide released from the precursor form of NTSR3/Sortilin.
Here, we show for the first time that the propeptide is present into
blood circulation and is able to inhibit currents mediated by the
TREK-1 channel. Due to higher affinity and for a better efficacy,
this study was mainly focused on the use of spadin. Using TREK-1
deficient mice and animal models of depression, our laboratory
has recently identified the TREK-1 channel as a new target for
depression and its blockers as potential antidepressant drugs [1].
With the identification of spadin as an antagonist of TREK-1, this
work validates the TREK-1 channel as a good target for the
development of drugs for the treatment of depression [1,40]. In
humans, the Star*D study has reported the functional role of this
particular potassium channel in mood regulation and in resistance
to antidepressant treatments [4], strengthening the idea that
TREK-1 represents an attractive pharmacological target for the
development of new types of antidepressant drugs.
This is of high relevance since depression is a devastating illness
that affects ,17% of the population at some point in life, resulting
in major social and economic consequences [41]. Designing
effective treatments for this serious disorder is challenging, in part
because unraveling the exact changes that lead to this psychiatric
disorder is particularly difficult. In addition to the inherent
complexity of the disease itself, it is not clear how antidepressant
drugs work. Most antidepressants increase levels of the mono-
amine serotonin (5-HT) and/or noradrenaline (NA), suggesting
that biochemical imbalances within the 5-HT/NA systems may
underlie the pathogenesis of this disorder [17,27,39]. To date, the
mainstay of antidepressant treatments is constituted by SSRIs,
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which inhibit the 5-HT reuptake pump. Although antidepressant
treatments significantly improve the therapeutic outlook for
depressed patients, there are still too many patients who do not
respond to initial treatments. In the case of response, side effects
are often observed, as well as a delay in the onset of therapeutic
efficiency and/or a partial rather than a full remission. Spadin,
which is a natural peptide, may alleviate these problems and
become a strong candidate to develop new efficient and fast-acting
antidepressant treatments. The first result of this work is the
identification of the NTSR3/Sortilin receptor as a novel TREK-1
partner protein. It interacts physically and functionally with
TREK-1 to modify its cell surface expression. NTSR3/Sortilin is a
member of the Vps10p-domain receptor family, which is
expressed in several tissues, including the brain. The interaction
between NTSR3/Sortilin and the N-terminal portion of the
precursor form of the NGF (pro-NGF) and the brain-derived
neurotrophic factor (pro-BDNF) represents a key event in the
process that controls neurotrophins-mediated cell survival and
death in developing neuronal tissue and post-traumatic neuronal
apoptosis [42]. NTSR3/Sortilin is involved in the sorting of
BDNF [43]. In regard to depression (for review see [44]), it is well
known that exogenous delivery of neurotrophic factors, such as
BDNF and/or neurotrophin 3 (NT-3) promotes the function,
sprouting, and regrowth of 5-HT neurons in the rat brain.
Infusions of BDNF into the DRN produced an antidepressant
effect, as evaluated by several learned helplessness paradigms.
Figure 7. Effects of Spadin on neurogenesis and CREB activation. (A–B) Spadin increased neurogenesis (A). Top, representative
photomicrographs of BrdU-labeled neurons in the dentate gyrus of the mouse hippocampus treated either with saline or with spadin (i.v., 1026 M)
for 4 d. Bottom, double labeling of BrdU-labeled neurons either with GFAP (glial marker) or with DCX (neuronal precursor marker), showing a co-
localization only with DCX, and not with GFAP. (B) Quantitation of BrdU positive cells of hippocampus treated with saline, fluoxetine, or spadin
(1025 M) for 4 d. 85% of BrdU-labeled cells were positive to DCX. Data are number of BrdU+ or DCX+ cells in mouse hippocampus (n=5) (F2,53 = 35.27;
***p,0.001 versus saline). (C) Quantitation of BrdU positive cells of hippocampus treated with saline, fluoxetine, or spadin (1025 M) for 15 d (n= 5)
(F2,53 = 19.43; *p,0.05, **p,0.01 versus saline). (D–G) Enhanced spadin treatment-induced CREB activation in the hippocampus, as assessed by
measuring phosphoCREB (pCREB) immunoreactivity. (D) Immunological distribution of pCREB in the mouse hippocampus after a 4 d i.v. treatment.
pCREB is phosphorylated in the cells near the subgranular zone (SGZ). (E) Quantification of pCREB positive cells/mm2 in hippocampal SGZ (n = 5) (t
test; ***p,0.001). (F) Western blot analysis of pCREB level in hippocampus treated with saline or spadin (1025 M). (G) Double immunofluorescent
staining (examples are indicated by arrows) for pCREB and DCX positive hippocampal neurons treated with saline or spadin (1025 M).
doi:10.1371/journal.pbio.1000355.g007
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Environmental stressors induce depression and decrease BDNF
mRNA, whereas antidepressants increase BDNF mRNA in the
brain via 5-HT2A and b-adrenoreceptor subtypes. Since we
observed an activation of 5-HT neurons by spadin, it would be
important to measure the influence of spadin both on protein and
mRNA levels of BDNF in order to determine whether its action is
correlated with the modulation of neurotrophin pathways.
NTSR3/Sortilin and spadin interact with the TREK-1 channel
as shown by immunoprecipitation of TREK-1 and NTSR3/
Sortilin from COS-7 cells co-expressing both proteins. TREK-1
and NTSR3/Sortilin are also colocalized in mouse cortical
neurons.
This work identifies a new function for spadin as a peptidic
antagonist of the TREK-1 channel. Until now, the full propeptide
(1–44) which contains the active spadin was known to display two
principal functions: (1) It binds the mature form of NTSR3/
Sortilin, hindering ligands to access the binding site of the
receptor, and (2) it antagonizes the effects of NT on microglial cell
migration [9,14]. To our knowledge, the propeptide has no
additional protein target. Here, we determined that spadin, but
not its N-terminal fragment Gln1-Arg16, displays identical binding
and activity properties as those of the full propeptide on the NT
system. Spadin binds specifically to TREK-1 with an affinity of
10 nM. Electrophysiological studies show that spadin efficiently
blocks the TREK-1 activity in COS-7 cells, cultured pyramidal
neurons, as well as CA3 hippocampal neurons in brain slices of
wild-type mice and not in kcnk22/2 mice, suggesting a specific
effect of spadin on the TREK-1 channel.
Finally, our data point out spadin as the first peptidic and fast-
acting antidepressant. Considering the blocking effect of spadin on
TREK-1 channels, we have analyzed in vivo its potential
antidepressant effects. In behavioral tests (FST, TST, and CMST),
predicting an antidepressant response [24], spadin-treated mice
show a resistance to depression as do kcnk22/2 mice [1]. This
antidepressant phenotype is even more marked in the LH and
NSF tests, which are considered as classical ‘‘rodent models of
depression’’ [13,31]. The antidepressant effect of spadin is not
specific to mice since it has also been observed in rats using the
FST test and in vivo 5-HT neuron firing recordings. More
importantly, our results indicate that molecular, biochemical, and
behavioral changes, that have previously been specifically linked to
long-term chronic treatment with SSRIs [45,46], are already
present as soon as 4 d when using i.v. spadin administration. The
fast-acting antidepressant potential of spadin, observed in vivo in
FST and TST tests, is further confirmed by its ability to activate
CREB function and neurogenesis in the adult mouse hippocampus
after a subchronic treatment. It is now well stated that
antidepressants share the common property to positively modulate
cellular growth and plasticity in mood-related brain areas. Indeed,
CREB activity and neurogenesis are considered as specific markers
of antidepressant action [47] but have never been observed before
2 wk of treatment when using classical antidepressants such as
SSRIs. By binding to cAMP response element (CRE) sites, CREB
mediates transcriptional responses to elevated levels of cAMP.
CRE-mediated gene transcription is upregulated after chronic
antidepressant treatment [48]. CREB upregulation activates
downstream targets such as the brain-derived growth factor
(BDNF) after antidepressant treatment by binding to CRE
elements located in the promoter region of the BDNF gene [49].
Here, we show that a 4-d chronic treatment with spadin is able to
enhance the pCREB/CREB ratio and consequently increases cell
division and proliferation in the SGZ. In addition, the therapeutic
potential of spadin appears to be specific of depression, in that it is
unable to affect anxiety-related behaviors. This is in good
agreement with the fact that TREK-1 deficient mice do not show
an anxiety-resistant phenotype [1]. In contrast, both spadin and
the deletion of the TREK-1 channel induce an hypoactivity of the
HPA axis when animals are exposed to stress.
As described in kcnk22/2 mice [1], spadin leads to an in vivo
increase in efficacy of 5-HT neurotransmission as evidenced by an
increased firing activity of DRN 5-HT neurons. Even if the
involvement of other aminergic systems in the pathophysiology of
depression is certainly non-negligible, it remains that the
facilitation of central 5-HT transmission constitutes the common
property of all the antidepressant strategies, which have proved
their efficiency. From a mechanical point of view, 5-HT1A
autoreceptor stimulation reduces DRN 5-HT neuronal firing
and, consequently, 5-HT neurotransmission [28]. Inhibition of
adenylate cyclase and activation of G-protein-coupled inwardly
rectifying K+ channels (GIRK) are involved in this negative
feedback [40]. The decrease in cAMP concentration (as a result of
reduced adenylate cyclase activity) in 5-HT neurons is also
thought to induce TREK-1 opening because of a consequent
reduction of phosphorylation of Ser333 by PKA [16]. According
to this model, spadin would induce a depolarization by closing
TREK-1 channels and, as described for TREK-1 deficient mice
[40], would therefore reduce the negative feedback on 5-HT
neurons, resulting in increased 5-HT neurotransmission and in
turn in antidepressant-like effects. Direct inhibition of TREK-1 by
spadin may also contribute to enhanced 5-HT neuron excitability.
Because (1) sortilin is the partner protein of the TREK-1 channel
and (2) both proteins are colocalized in 5-HT-enriched areas
known to be involved in the pathophysiology of depression such as
the prefrontal and cingulate cortice, amygdala, hippocampus,
nucleus accumbens, dorsal raphe, and hypothalamus [13], one
may infer that spadin acts predominantly through a modulation of
the brain 5-HT circuitry. Nevertheless, we cannot exclude that it
can also involve other neurotransmission systems. Whatever the
effector pathways though, the fact that spadin has no effects on
kcnk22/2 mice indicates that its action is first and foremost
mediated by a modulation of TREK-1 channels.
Our results show that spadin induces an 80% internalization of
these channels. We propose a model of regulation of TREK-1
expression and regulation by NTSR3/Sortilin receptor and spadin
(Figure 8). In physiological conditions (Figure 8A), TREK-1 and
NTSR3/Sortilin would associate in the TGN vesicle, where
spadin is hydrolyzed by furin. When TGN vesicles merge to the
plasma membrane, spadin would be released (as suggested in [14]
and shown in Figure 2B–C and Figure S3) and would bind either
NTSR3/Sortilin, TREK-1 channel, or both. This would lead to
the internalization of the TREK-1/Sortilin complex in early
endosome and subsequently to its degradation. In the presence of
an excess of spadin given by administration (Figure 8B), the rate of
internalized complexes would be increased, resulting in a total
disappearance of TREK-1 channels at the surface membrane.
This prediction is supported by the fact that 80% of the 125I-
spadin bound on the TREK-1 transfected COS-7 cells are
insensitive to an acid-NaCl wash (Figure 1F), indicating that the
complex spadin-TREK-1 is already internalized. The consequent
loss of TREK-1 channel activity would lead to an antidepressant
phenotype, as observed in TREK-1 deficient mice. However,
overall the inhibitory action of spadin on TREK-1 function is
likely the consequence of both its ability to induce channel
internalization and its direct effect on the channel current.
Conclusions
Spadin can be considered as a natural endogenous antidepres-
sant and constitutes the first peptide identified as an antidepressant
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with a rapid onset of action. Due to these peculiar properties,
spadin brings a new concept to address the treatment of
depression. To date, spadin is also the first blocker of TREK-1
channel identified, which not only is of relevance in the field of
depression but also constitutes a useful tool to further understand
the role of TREK-1 channels in other neurological pathologies.
Finally, this work shows the development of a reliable method for
dosing the propeptide and spadin by using AlphaScreen
technology. The last point is crucial to use in the future spadin
as a marker of depression by dosing spadin in the serum of
depressed patients, and to help for setting clinical preventive
protocols. Detecting and preventing the depression certainly could
decrease the economic burden of this disease, which is estimated to
be $44 billion per year in the United States.
Materials and Methods
All experiments were carried out on 20–25 g male C57Bl/6J
(Janvier France Breeding) and on TREK-1 deficient mice
(kcnk22/2) according to policies on the care and use of laboratory
animals of European Community legislation 86/609/EEC. The
local Ethics Committee (CREEA Coˆte d’Azur) approved the
experiments (protocol number NCE2008-08/09-0). The behav-
ioral protocols are described in the Supporting File (Text S1).
Drugs and Chemicals
The propeptide named spadin, with the following amino acid
sequence, Y-APLPRWSGPIGVSWGLR (GenBank NM_019972
for mouse), and the N-terminal fragment QDRLDAPPP-
PAAPLPR were synthetized by Gencust (France). The stock
solution was dissolved in distilled water at a concentration of
1023 M, and spadin solution was then diluted in NaCl 0.9% to
reach the different treatment concentrations. The i.c.v. injection
was performed under isoflurane anesthesia. Mice were anesthe-
tized by inhalation of 2% isoflurane mixed with 30% oxygen and
70% nitrous oxide. Spadin (5 ml) was stereotaxically administered
30 min prior to the behavioral test by an injection needle that was
lowered bilaterally into the lateral ventricle of the mouse
positioned on a stereotaxic frame, by using the coordinates
referred from Paxinos and Flanklin (related to bregma: AP:
20.46 mm, ML: 1.25 mm, and DV: 22.25 mm). The injection
needle was connected to a Hamilton syringe (10 ml) positioned in a
micropump and delivered the drug solution at a rate of 1 ml/min
for 5 min. Fluoxetine (TEVA Sante´, France) and diazepam,
diluted in NaCl 0.9%, were used at the concentration of 3 mg and
0.5 mg per kg body weight, respectively, in i.p. administration.
BrdU (Sigma-Aldrich, St Quentin Fallavier, France) was diluted in
Tris-buffered saline (0.1 M in NaCl 0.9%, pH:7.6). All other
chemicals were from Sigma (St Quentin Fallavier, France). Stock
solutions were prepared in H2O except otherwise mentioned,
frozen, and diluted before the experiment. Arachidonic acid that
was prepared at a concentration of 0.1 M under argon in 100%
ethanol, glibenclamide 100 mM in dimethyl sulfoxide (DMSO),
and fluoxetine 1.3 mM in glycerol.
Cell Culture
COS-7 and C13NJ cells were cultured in DMEM supplemented
with 10% FBS and 50 mg/ml gentamycin at 37uC under 5% CO2.
b-TC3 cells were grown in RPMI 1640 supplemented with 2.5%
FBS, 50 mM b-mercaptoethanol, 10 mM HEPES, 1 mM Sodium
pyruvate, and 50 mg/ml gentamycin. Cells were maintained at
37uC under 5% CO2.
Cortical neurons were prepared from 14 old mouse embryos,
whereas hippocampal neurons were prepared from newborn mice.
Briefly, dissected brain areas were dissociated and neurons were
plated on polylysine-treated 35 or 60 mm dishes and maintained
in culture in Neurobasal medium supplemented with B27,
Glutamax, and antibiotics for 2 to 3 wk before to be used for
electrophysiological or biochemical experiments.
Characterization of the interaction between NTSR3/
Sortilin, spadin, and TREK-1. Experiments were per-
formed using COS-7 cells (106 cells per diameter 100 dish)
Figure 8. Schematic model of TREK-1 regulation by NTSR3/Sortilin and Spadin. In physiological conditions (A) the concentration of spadin
that would be released from vesicles of the Trans Golgi Network (TGN) is not sufficient to completely abolish the channel activity, by internalization
via Early Endosome (E.E.) vesicles, direct blockade, or both. Conversely, under spadin treatment (B) the amount of spadin is sufficient to internalize all
channel molecules and consequently to abolish the channel activity.
doi:10.1371/journal.pbio.1000355.g008
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transfected with TREK-1 (2 mg/dish) in the presence or in the
absence of NTSR3/sortilin (2 mg/dish) using the DEAE-dextran
protocol.
Immunoprecipitation. Cortical neurons or COS-7 cells
transfected with TREK-1 and NTSR3/Sortilin were lysed in
20 mM Tris-HCl pH 7.5, 50 mM NaCl, 50 mM NaF, 30 mM
sodium pyrophosphate, 5 mM EGTA, 10% glycerol, 1% Triton
X100, 1 mM PMSF, 1 mM Na3VO4, and 5 mg/ml aprotinin
(lysis buffer) for 1 h at 4uC. Solubilized proteins were clarified by
centrifugation at 15,0006g for 15 min at 4uC. Supernatants were
immunoprecipitated by using either the rabbit polyclonal anti-
NTSR3 antibody (1:250) (Alomone) or the rabbit polyclonal anti-
TREK-1 antibody (1:250) (Alomone) in the presence of 40 ml
protein-A Affarose (Interchim) overnight at 4uC. Protein
complexes were recovered by centrifugation at 15,0006g for
5 min at 4uC and washed twice with the lysis buffer.
Immunoprecipitates were resuspended in SDS buffer, separated
by SDS-PAGE, transferred onto nitrocellulose, and revealed either
with anti-NTSR3 or with anti-TREK-1 (1:1000). Bound
antibodies were visualized using HRP-conjugated goat anti-
rabbit IgG TrueBlot.
Sub-cellular fractionation. Plasma membranes were
prepared from COS-7 cells transfected with TREK-1 alone or
with NTSR3/Sortilin according to the protocol described by
Clancy and Czech [50]. 30 mg of crude homogenates or purified
plasma membranes were submitted to Western blot analysis using
the rabbit polyclonal anti-TREK-1 antibody (1:500). Alternatively,
plasma membranes of COS-7 cells transfected with TREK-1
alone or with NTSR3/Sortilin were labeled with 0.5 mg/ml
Sulfo-NHS-SS-Biotin for 30 min at 4uC. Cells were recovered
with the lysis buffer used for immunoprecipitation for 1 h at 4uC
and solubilized proteins were clarified by centrifugation at
15,000 g for 15 min at 4uC before to be precipitated using
streptavidin-agarose overnight at 4uC. Protein complexes were
recovered, separated by SDS-PAGE, and submitted to Western
blot analysis as described above.
Spadin iodination. Spadin (2 nmol) was iodinated with
125INa (0.5 nmol) using lactoperoxidase as oxidant.
Monoiodinated spadin (on Tyr0) was purified by HPLC using a
Waters apparatus equipped with a RP18 Lichrosorb column.
Elution was carried out at a flow rate of 1 ml/min with a linear
gradient of increasing concentration of acetonitrile in water
containing 0.1% TFA from 30% to 60% in 36 min. The
iodinated peptide was eluted at 24 min.
Binding assays. For competition experiments, homogenates
from TREK-1 transfected COS-7 or C13NJ cells were incubated
with 0.2 nM 125I-spadin or 125I-NT (200,000 cpm in 250 ml)
iodinated and purified as previously described [51]. Incubations
were performed in 50 mM Tris-HCl, pH 7.4 containing 0.1%
BSA in the presence of increasing concentrations of non-
radioactive spadin or NT (10210 to 1025M). Incubations were
terminated by addition of 2 ml of ice-cold binding buffer followed
by filtration through cellulose acetate filters (Sartorius, Go¨ttingen,
Germany) and washing twice with 2 ml of ice-cold buffer.
Radioactivity on filters was counted with a gamma-counter.
Wound-healing assay. A cell-free zone was created within a
semi-confluent monolayer of microglial culture by scratching cells
off with a pipette tip. We analyzed by time-lapse microscopy how
cells repopulated the cell-free zone, as already described [17].
Internalization. Cells, grown on 12 mm multiwell-dishes,
were incubated with 0.2 nM 125I-spadin for various times at 37uC
in an Earle’s Tris-Hepes buffer (cell binding buffer). Incubations
were terminated by washing cells twice with the binding buffer or
with the same buffer containing 0.5 M NaCl, pH 4, for 2 min to
remove non-sequestrated radioactivity (acid-NaCl wash). Cells
were harvested with 1 ml of 0.1 N NaOH and counted in a
gamma-counter. Non-specific binding was determined in the
presence of 10 mM unlabeled spadin.
TREK-1/NTSR3/Sortilin colocalization experiments.
Hippocampal neurons were first washed for 5 min in Phosphate-
Buffered Saline (PBS), then fixed with 4% paraformaldehyde in
PBS for 20 min at room temperature. Coverslips were rinsed twice
with PBS and incubated with 50 mM NH4Cl in PBS for 10 min
to quench excess of free aldehyde groups. After 20 min in PBS
containing 10% Horse Serum (HS), cells were labeled with a goat
polyclonal anti-NTSR3/Sortilin (1/100) (Santa Cruz) and a rabbit
anti-TREK-1 [16] (1/3,000), for 1 h at room temperature in PBS
containing 5% HS. Cells were rinsed three times in PBS, then
incubated at room temperature in PBS containing FITC
conjugated donkey anti-goat antibody (1/1,000) and a Texas
Red conjugated donkey anti-rabbit antibody (1/1,000) in PBS
containing 5% HS for 45 min. After two washes with PBS and one
with water, coverslips were mounted on glass slides with mowiol
for confocal microscopy examination.
Electrophysiology
COS-7 cells. All electrophysiological experiments were done
on COS-7 cells seeded at a density of 20,000 cells/35-mm dish
24 h before transfection. Cells were transfected by the classical
DEAE-dextran method with TREK-1-GFP plasmids (0.1 mg/mL).
Cells were visualized 48–72 h after transfection using fluorescence.
The whole-cell patch-clamp technique was used to evaluate
TREK-1 potassium channel current by using a RK 400 patch-
clamp amplifier (Axon Instruments, USA), as previously described
[52]. Currents were lowpass filtered at 3 kHz, digitized at 10 kHz
using a 12-bit analog-to-digital converter. Patch-clamp pipettes
were pulled from borosilicate glass capillaries and had a resistance
of 1.8–3 MU`. The bath solution contained (in mM) 150 NaCl, 5
KCl, 3 MgCl2, 1 CaCl2, and 10 HEPES, adjusted to pH 7.4 with
NaOH; the patch pipette solution contained (in mM) 155 KCl, 3
MgCl2, 5 EGTA, and 10 HEPES, adjusted to pH 7.2 with KOH.
Cells were clamped at 280 mV and voltage changes were either
applied by ramp (from 2100 to 50 mV, 1 s in duration) or by step
(from 2100 to 40 mV, 1.5 s in duration). Cells were continuously
superfused with a microperfusion system. The pipette capacitance
was not subtracted from total membrane capacitance and there
was no leak subtraction. All experiments were done at room
temperature (21uC to 22uC) and in the presence of a cocktail of
potassium channel inhibitors (K+ blockers: 10 mM tetraethyl
ammonium (TEA), 3 mM 4-aminopyridine (4-AP), 50 nM
charybdotoxin, 10 mM glibenclamide, 100 nM apamin).
Pclamp software was used to analyze currents recorded in the
whole-cell mode measured at 0 mV. Results are expressed as
means 6 SD. To obtain the IC50 value for dose-dependent
inhibition, experimental data were fitted with a standard sigmoidal
function.
b-TC3 cells. Native currents elicited by these cells were
recorded in the whole-cell configuration of the patch-clamp
technique (as described for COS-7 cells) and in the presence of K+
blockers.
Brain slices of hippocampus. 12–27-d-old mice were
anaesthetized with 1% halothane. Following decapitation, brains
were rapidly removed and placed in cold phosphate/bicarbonate
buffered solution (PBBS, 4uC) composed of (mM) 125 NaCl, 2.5
KCl, 0.4 CaCl2, 1 MgCl2, 25 glucose, 1.25 NaH2P04, 26
NaHC03, and pH 7.4 when bubbled with 95% O2/5% CO2.
Transversal 250 mm thick hypothalamic slices cut with a vibrating
microtome (Microm, Francheville, France) were then transferred
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to an incubation chamber maintained at 34uC in oxygenated
PBBS. After 1 h, slices were transferred to another incubation
chamber at room temperature (22–25uC) filled with PBBS
containing 2 mM CaCl2.
For current measurements using the whole-cell patch-clamp
technique, brain slices were placed under a Nomarski microscope
(Zeiss, Le Pecq, France) equipped with infrared video camera
(Axiocam, Zeiss, Le Pecq, France) in a recording chamber
superfused at a flow rate of 1 ml.min21 with HEPES solution
containing (in mM) 140 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 10
Glucose, 10 Hepes, and pH 7.4. Pictures were taken by using a
digital camera (Axiocam, Zeiss) connected to image-acquisition
software (Axiovision). Recordings were made at room temperature
(25uC62uC) using an Axopatch 200B (Axon Instruments, Foster
City, CA, USA). Patch-clamp pipettes made from borosilicate
glass capillary (Hilgenberg, Masfeld, Germany) had a resistance of
4–10 MV when filled with the internal solution containing (mM)
135 KCl, 5 NaCl, 2 MgCl2, 5 EGTA, and 10 Hepes (pH adjusted
to 7.25 with KOH). Values of access resistance ranged from 12 to
20 MV and were not compensated. Measurements were made 2–
3 min after obtaining the whole-cell to ensure dialysis. Changes of
extracellular solution were obtained by a fast multi-barrel delivery
system positioned close to the cell tested. Stock solutions were
prepared in H2O except otherwise mentioned, frozen, and diluted
before the experiment. Arachidonic acid, which was prepared at a
concentration of 0.1 M under Argon in 100% ethanol, glibencla-
mide 100 mM in dimethyl sulfoxide (DMSO), and fluoxetine
1.3 mM in glycerol.
Statistical significance between groups (average data expressed
as mean 6 SEM, n= number of neurons) was tested using the
Student’s t test or the ANOVA followed by t test, and were
considered significant at p,0.05. Statistical analysis was done
using SigmaPlot (Jandel) and Origin (Microcal) softwares.
Extracellular unitary recordings of DRN 5-HT
neurons. As previously described [1], single-barreled glass
micropipettes (recording electrodes) were filled with a 2 M NaCl
solution saturated with Fast Green FCF, resulting in an impedance
of 2–5 MV. Mice were anaesthetized with chloral hydrate
(400 mg/kg, i.p., using a 2% solution) and placed in a
stereotaxic frame equipped with the Stoelting ‘‘just for mouse’’
adaptor. Electrodes were positioned 0.5–1 mm posterior to the
interaural line on the midline and were then lowered into the
DRN, usually attained at a depth of 2.5 mm from the brain
surface. 5-HT neurons were then encountered over a maximal
distance of 1 mm. They were identified using the following
criteria: a slow (0.5–2.5 Hz) and regular firing rate and long-
duration (0.8–1.2 ms) action potentials, with a positive-negative
spike [1]. Spikes were computed by using the Spike 2 software, so
that the firing rate was calculated as the mean number of events
occurring within a 10 s period. For each neuron, the discharge was
monitored during 60 s. Each mouse received either spadin
(1025 M in a 100 ml bolus) or its vehicle (saline). Starting
30 min after the injection, 3 to 4 successive descents were
performed along the DRN, for a total of 4–8 cells recorded per
animal. Recordings were performed for a maximal duration of 4 h
post-injection.
Measurement of Hippocampal Neurogenesis
Twenty-four hours after the injection of BrdU (120 mg per kg of
body weight in a 300 ml bolus), mice were euthanized and
transcardially perfused with 4% cold paraformaldehyde. Serial
sections of the brains were cut (40 mm) throughout the entire
hippocampus on a vibratome (Leica). Every sixth section
throughout the hippocampus was processed for BrdU or DCX
immunohistochemistry, as previously described [1]. For each
immunodetection, slides were first incubated overnight at 4uC with
a mouse monoclonal anti-BrdU antibody (1:200; Becton-Dick-
inson) or a goat anti-DCX (1:400; Santa Cruz Laboratories). For
chromogenic immunodetection, sections were then incubated for
1 h in biotin-conjugated species-specific secondary antibodies
(1:100; Vector Laboratories) followed by a peroxidase-avidin
complex solution according to the manufacturer’s protocol. The
peroxidase activity of immune complexes was visualized with DAB
staining using the VectaStain ABC kit (Vector Laboratories). For
fluorescent double-labeling, performed to determine the cell
phenotype, sections were incubated overnight at 4uC with anti-
sheep BrdU (1:200, Interchim), anti-goat DCX (1:200, Santa Cruz
Laboratories), or an anti-GFAP (glial fibrillary acidic protein,
marker for astrocytes, 1:250, Dako). Antibodies were revealed with
anti-IgG Alexa 488 or 594-coupled antibodies (1:400; Molecular
Probes). All BrdU-labeled cells in the granular cell layer and SGZ
were counted in each section (n=10 and 5 mice per group) at
4006 and 1,0006 magnification under a light microscope
(Olympus) by an experimenter blinded to the study code. The
total number of BrdU-positive cells per section was multiplied by 6
to obtain the total number of cells per dentate gyrus. The counting
of BrdU/DCX labeled cells was performed using a Laser
Scanning Confocal Microscope (TCS SP, Leica) equipped with
a DMIRBE inverted microscope.
Assessment of CREB Activation
Total CREB and pCREB Western blotting. Mouse brains
were dissected on ice. Isolated hippocampi (1–2 mg wet tissue/
100 ml) were homogenized in a solubilization buffer containing
20 mM HEPES (pH:7.9), 0.4 M NaCl, 20% (v/v) glycerol, 1% (v/
v) Nonidet P-40, 5 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA,
and protease inhibitor cocktail using a dounce homogenizer. The
homogenates were centrifuged 30 min at 15,0006g at 4uC.
Supernatants were stored at 270uC until further use. Protein
concentrations were measured using conventional Bradford’s
method. Samples (50 mg proteins from each experimental
group) were resuspended in SDS buffer, sonicated, boiled for
5 min before loading on 10% SDS PAGE gels, and
electrophoresed for 2 h at 60 mA. Proteins were then
transferred from gels onto Hybond-PVDF membranes
(Amersham Biosciences) in blotting buffer (156 mM Tris, 1 M
glycine, PBS) for 90 min at 80 mA and blocked with 5% skim milk
(Regilait) in PBS for 2 h at room temperature. Membranes were
incubated with the monoclonal anti-pCREB antibody (1:1,000,
Cell Signaling Technology) overnight at 4uC. Total CREB or
tubulin contents were determined after stripping by using 1/1,000
dilution of anti-CREB antibody (Cell Signaling Technology) and
1/1,000 dilution of anti-tubulin antibody (Sigma-Aldrich). After
washing in 0.1% Tween/PBS (four times, 15 min each), secondary
anti-mouse or anti-rabbit horseradish peroxidase-conjugated
antibody (Amersham Biosciences, 1/10,000) was used for 1 h at
room temperature. Detection of blotted proteins was performed
using ECL plus Western blotting detection reagents (Amersham
Biosciences, Orsay, France) with a Las-3000 imaging system
(Fujifilm). Relative intensities of the labeled bands were analyzed
by densitometric scanning using ImageJ imaging system. CREB
activation was expressed as the ratio between pCREB and total
CREB present in each sample.
pCREB immunostaining in hippocampal sections. Free
floating sections were permeabilized in 0.1% Triton/PBS for
10 min and blocked with 3% goat serum/PBS for 2 h at room
temperature followed by a single wash in PBS. Sections were then
incubated with the monoclonal anti-pCREB antibody (1:300, Cell
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Signaling Technology) overnight at 4uC. After three washes in
PBS, sections were then incubated in biotinylated horse anti-rabbit
IgG (Jackson ImmunoResearch, diluted 1:15,000) for 2 h at room
temperature. pCREB expression was visualized by 3.39-
diaminobenzidine (DAB) staining using the VectaStain ABC kit
(Biovalley). All sections were washed and mounted with Entellan.
For BrdU/pCREB immunofluorescence staining, free floating
sections of mice injected with BrdU were incubated with the
primary antibodies, anti-rabbit pCREB (1:500, Cell Signaling
Technology), and anti-mouse BrdU (1:40, Becton-Dickinson).
After three washes in PBS, sections were then incubated in anti-
IgG Alexa 488- or 594-coupled antibodies (Molecular Probes) for
1 h at room temperature. After drying sections in the dark boxes
for 2 h, they were mounted with Vectashield (Vector
Laboratories). Confocal microscopy observations were performed
with the Laser Scanning Confocal Microscope (TCS SP, Leica)
equipped with a DMIRBE inverted microscope, using a Plan Apo
636/1,4 NA oil immersion objective.
Corticosterone assay. Mice were individually housed for at
least 12 h before blood sample collection. Serum samples,
collected in the morning, were obtained by retroorbital puncture
before and 30 min after the end of a 10 min tube restraint. Levels
of corticosterone were measured by radioimmunoassay using a
commercially available kit (MP Biomedicals).
Supporting Information
Figure S1 C13NJ wound-healing assay. A cell-free zone was
created within a semi-confluent monolayer with a pipette tip. We
analyzed by time-lapse microscopy how cells repopulated the cell-
free zone. The 100% of migrating cells was calculated by
stimulation of cell migration with 10% of Fetal Calf Serum (FCS).
Found at: doi:10.1371/journal.pbio.1000355.s001 (0.13 MB
TIF)
Figure S2 Comparative effects of N-terminal propep-
tide fragment Gln1-Arg16 and spadin on TREK-1
channel activity: in COS-7 transfected cells. After 90 s of
application, the N-terminal propeptide fragment Gln1-Arg16 (Nt-
Peptide 1-16) was unable to inhibit the current increase induced by
a 10 mM arachidonic acid (aa) application (the current value
continued to increase) (A), whereas in the same experimental
conditions spadin inhibited the aa-induced increase (B).
Found at: doi:10.1371/journal.pbio.1000355.s002 (0.16 MB
TIF)
Figure S3 Alpha Screen assays. Competition curve obtained
with four groups (nu 2 to 5) of 6 mice. Values obtained are
compared to the standard curve.
Found at: doi:10.1371/journal.pbio.1000355.s003 (0.20 MB
TIF)
Figure S4 Effects of spadin on cultured pyramidal
neurons from hippocampus. (A) Cultured pyramidal neuron
from hippocampus, with on top, the patch-clamp pipette. Neurons
were chosen according to their morphology. (B) Current recorded
in response to ramps of potential obtained in the various
conditions indicated (aa, arachidonic acid: 10 mM; Spadin:
1 mM; Fluoxetine: 20 mM). Neurons were recorded in the whole-
cell configuration of the patch-clamp technique. In voltage-clamp,
ramps of potential from 290 mV to 70 mV were applied every
10 s. The % variation of the current amplitude was always
measured at 250 mV. The currents were recorded in response to
such ramps in control conditions and in the presence of a cocktail
of potassium blockers suitable to isolate the TREK currents
(10 mM tetraethyl ammonium (TEA), 3 mM 4-aminopyridine (4-
AP), 50 nM charybdotoxin, 10 mM glibenclamide, 100 nM
apamin). In the presence of the potassium blockers, the remaining
current was increased by about 50% by 10 mM arachidonic acid in
7 out of 70 recorded neurons (B–C), suggesting the activation of a
TREK current. This acid-arachidonic evoked current (putative
TREK current) was 49.7%616.38% (n= 6) blocked by 1 mM
spadin and fully blocked by 20 mM fluoxetine (B–D). The blocks
were reversible. (C) Time course of spadin and fluoxetine effects.
Applications are indicated by the horizontal bars.
Found at: doi:10.1371/journal.pbio.1000355.s004 (2.03 MB
TIF)
Figure S5 Antidepressant effect of spadin in rats. (A, B)
Effect of spadin on the average DRN 5-HT neuron firing rate.
Spadin (1025 M in a 500 ml bolus) or its vehicle (saline) was i.p.
administered. Recordings started 30 min after the injection and
were performed for a maximal duration of 210 min thereafter. (A)
5-HT neuron firing activity, calculated on the basis of all the cells
recorded within the successive tracks performed along the DRN.
Values at the bottom of each column indicate the total number of
neurons recorded (n = 4 rats in both groups). In saline-injected
rats, we found a value of 1.1860.13 Hz, whereas it reached
2.6660.36 Hz in the group treated with spadin (1025M in a
500 ml bolus, i.p.) [one-way ANOVA, F(1, 68) = 13.06, p,0.001].
This effect corresponds to an increase of 125%, a value strikingly
similar to that of 146% observed in the mice experiments. (B)
Again, and as illustrated, several neurons found in spadin-injected
rats discharged at up to 4, 5, or even 6 Hz, whereas most of the
frequencies found in the saline group were in a normal (0.8–
1.6 Hz) range. Samples of ‘‘descents’’ performed along the DRN,
showing typical integrated firing rate histograms in a vehicle- (left
panel), or in a spadin-treated (right panel), animal. Each cluster
represents the electrical activity of one neuron, each bar
representing the average number of recorded action potentials
per 10 s. Insets, examples of action potential waveforms of 5-HT
neurons. (C) Acute antidepressant effects of Spadin in Forced
Swimming Test (FST). Spadin (1025 M), Fluoxetine (20 mg/kg),
or Saline solutions were injected 30 min before the test in rats
(n = 10 per group). Spadin-treated rats had a shorter time of
immobility comparable to those obtained in fluoxetine-treated
animals (one-way ANOVA, F2, 26 = 16.66, ***p,0.001, **p,0.01
versus saline-treated rats).
Found at: doi:10.1371/journal.pbio.1000355.s005 (0.32 MB
TIF)
Figure S6 Mouse locomotion activity. To determine
whether spadin induced a change in locomotor activity, mice
(n = 8 per group) were injected with the saline solution or spadin
(1025M in 100 ml bolus, i.p.) 30 min before starting the test
session. Locomotor activity was monitored individually for 24 h
using an infrared photobeam activity monitoring system (Ime-
tronic, Pessac, France), which measured consecutive horizontal
beam breaks. Testing was in transparent plastic cages (4362
0620 cm3) with fresh bedding in a grid of 8 cm horizontal
infrared beams. Locomotor activity was defined as breaking of
consecutive photobeams. Mice were given 1 h habituation session
before being treated with spadin or saline. Movements were
recorded and totalized for each 5 min period during the first hour
and then by 10 min time sections for the next 23 h. Six periods
were pooled to obtain data for 1 h of time. Different movements
were monitored: the coming-and-going between the back and the
front of the cage, climbing, and other movements in the back or
the front of the cage. Data are the mean value of 8 animals per
condition, bars represent SEM. Mice were kept under standard
laboratory conditions: 12:12 light-dark cycle with free access to
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food and water during the experiment. There was no significant
difference in locomotor activity between spadin- and saline-treated
mice within 1 or 24 h after the drug injection.
Found at: doi:10.1371/journal.pbio.1000355.s006 (0.53 MB
TIF)
Text S1 Supplementary material and methods.
Found at: doi:10.1371/journal.pbio.1000355.s007 (0.07 MB
DOC)
Acknowledgments
We are very grateful to Dr. F. Lesage for the TREK-1 antibody and to
Professor J. M. Vaugeois for fruitful discussions and criticisms of the
manuscript.
Author Contributions
The author(s) have made the following declarations about their
contributions: Conceived and designed the experiments: JM GL EC CH
MB. Performed the experiments: JM OP GL ED SBD CG MEY CW AG
EC ST GC AC TC JLN CH MB. Analyzed the data: JM OP GL ED SBD
CG MEY CW AG EC ST TC JLN CH MB. Contributed reagents/
materials/analysis tools: OP CG MEY CW ST AC GG MB. Wrote the
paper: JM CH MB.
References
1. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thu¨mmler S, et al. (2006)
Deletion of TREK-1, a background potassium channel, results in a depression-
resistant phenotype. Nature Neurosci 9: 1134–1141.
2. Chemin J, Girard C, Duprat F, Lesage F, Romey G, et al. (2003) Mechanisms
underlying excitatory effects of group I metabotropic glutamate receptors via
inhibition of 2P domain K+ channels. EMBO J 22: 5403–5411.
3. Lesage F, Lazdunski M (2000) Molecular and functional properties of two pore
domain potassium channels. Am J Physiol 279: 793–801.
4. Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, et al. (2008)
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant
response: association of TREK1 and treatment resistance in the STAR(*)D
Study. Neuropsychopharmacology 33: 2810–2819.
5. Sandoz G, Thummler S, Duprat F, Feliciangeli S, Vinh J, et al. (2006)
AKAP150, a switch to convert mechano-, pH- and arachidonic acid-sensitive
TREK K(+) channels into open leak channels. EMBO J 25: 5864–5872.
6. Sandoz G, Tardy MP, Thummler S, Feliciangeli S, Lazdunski M, et al. (2008)
Mtap2 is a constituent of the protein network that regulates twik-related K+
channel expression and trafficking. J Neurosci 28: 8545–8552.
7. Hervieu GJ, Cluderay JE, Gray CW, Green PJ, Ranson JL, et al. (2001)
Distribution and expression of TREK-1, a two-pore-domain potassium channel,
in the adult rat CNS. Neuroscience 103: 899–919.
8. Sarret P, Krzywkowski P, Segal L, Nielsen MS, Petersen CM, et al. (2003)
Distribution of NTS3 receptor/sortilin mRNA and protein in the rat central
nervous system. J Comp Neurol 461: 483–505.
9. Mazella J, Zsurger N, Navarro V, Chabry J, Kaghad M, et al. (1998) The 100-
kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor.
J Biol Chem 273: 26273–26276.
10. Nielsen MS, Madsen P, Christensen EI, Nykjaer A, Gliemann J, et al. (2001)
The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the
VHS domain of the GGA2 sorting protein. Embo J 20: 2180–2190.
11. Lefrancois S, Zeng J, Hassan AJ, Canuel M, Morales CR (2003) The lysosomal
trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin.
Embo J 22: 6430–6437.
12. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, et al. (2004) Sortilin is
essential for proNGF-induced neuronal cell death. Nature 427: 843–
848.
13. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression.
Nature 455: 894–902.
14. Munck Petersen C, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, et al. (1999)
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand
binding. Embo J 18: 595–604.
15. Westergaard UB, Sorensen ES, Hermey G, Nielsen MS, Nykjaer A, et al. (2004)
Functional organization of the sortilin Vps10p domain. J Biol Chem 279:
50221–50229.
16. Maingret F, Lauritzen I, Patel AJ, Heurteaux C, Reyes R, et al. (2000) TREK-1
is a heat-activated background K(+) channel. EMBO J 19: 2483–2491.
17. Martin S, Vincent JP, Mazella J (2003) Involvement of the neurotensin receptor-
3 in the neurotensin-induced migration of human microglia. J Neurosci 23:
1198–1205.
18. Taouji S, Dahan S, Bosse´ R, Eric C (2009) Current screen based on the
AlphaScreen technology for deciphering cell signaling pathways. Current
Genomics 10: 93–101.
19. Mills NL, Shelat AA, Guy RK (2007) Assay optimization and screening of RNA-
protein interactions by AlphaScreen. J Biomol Screen 12: 946–955.
20. Caruso ME, Jenna S, Beaulne S, Lee EH, Bergeron A, et al. (2005) Biochemical
clustering of monomeric GTPases of the Ras superfamily. Mol Cell Proteomics
4: 936–944.
21. Patel AJ, Honore E, Maingret F, Lesage F, Fink M, et al. (1998) A mammalian
two pore domain mechano-gated S-like K+ channel. EMBO J 17: 4283–4290.
22. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model
sensitive to antidepressant treatments. Nature 266: 730–732.
23. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new
method for screening antidepressants in mice. Psychopharmacology (Berl) 85:
367–370.
24. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, et al. (2002) Neurobiology
of depression. Neuron 34: 13–25.
25. Kameyama T, Nagasaka M, Yamada K (1985) Effects of antidepressant drugs
on a quickly-learned conditioned-suppression response in mice. Neuropharma-
cology 24: 285–290.
26. Caldarone BJ, George TP, Zachariou V, Picciotto MR (2000) Gender
differences in learned helplessness behavior are influenced by genetic
background. Pharmacol Biochem Behav 66: 811–817.
27. Haddjeri N, Blier P, de Montigny C (1998) Long-term antidepressant treatments
result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18:
10150–10156.
28. Blier P, de Montigny C (1999) Serotonin and drug-induced therapeutic
responses in major depression, obsessive-compulsive and panic disorders.
Neuropsychopharmacology 21: 91S–98S.
29. Blier P (2001) Possible neurobiological mechanisms underlying faster onset of
antidepressant action. J Clin Psychiatry 62 Suppl 4: 7–11; discussion 37–40.
30. Cryan JF, Page ME, Lucki I (2005) Differential behavioral effects of the
antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced
swim test following chronic treatment. Psychopharmacology (Berl) 182:
335–344.
31. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003) Requirement
of hippocampal neurogenesis for the behavioral effects of antidepressants.
Science 301: 805–809.
32. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW (1996)
Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A
93: 3908–3913.
33. Holsboer F (2001) Stress, hypercortisolism and corticosteroid receptors in
depression: implications for therapy. J Affect Disord 62: 77–91.
34. Hermann G, Beck FM, Tovar CA, Malarkey WB, Allen C, et al. (1994) Stress-
induced changes attributable to the sympathetic nervous system during
experimental influenza viral infection in DBA/2 inbred mouse strain.
J Neuroimmunol 53: 173–180.
35. Cryan JF, Holmes A (2005) The ascent of mouse: advances in modelling human
depression and anxiety. Nat Rev Drug Discov 4: 775–790.
36. Rodgers RJ (1997) Animal models of ‘anxiety’: where next? Behav Pharmacol 8:
477–496; discussion 497–504.
37. Malberg JE, Schechter LE (2005) Increasing hippocampal neurogenesis: a novel
mechanism for antidepressant drugs. Curr Pharm Des 11: 145–155.
38. Carlezon WA, Jr., Duman RS, Nestler EJ (2005) The many faces of CREB.
Trends Neurosci 28: 436–445.
39. Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, et al.
(2005) Doublecortin expression levels in adult brain reflect neurogenesis.
Eur J Neurosci 21: 1–14.
40. Gordon JA, Hen R (2006) TREKing toward new antidepressants. Nat Neurosci
9: 1081–1083.
41. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. (2005)
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the
National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593–602.
42. Hermey G (2009) The Vps10p-domain receptor family. Cell Mol Life Sci 66:
2677–2689.
43. Chen ZY, Ieraci A, Teng H, Dall H, Meng CX, et al. (2005) Sortilin controls
intracellular sorting of brain-derived neurotrophic factor to the regulated
secretory pathway. J Neurosci 25: 6156–6166.
44. Altar CA (1999) Neurotrophins and depression. Trends Pharmacol Sci 20:
59–61.
45. Lucas G, Debonnel G (2002) 5-HT4 receptors exert a frequency-related
facilitatory control on dorsal raphe nucleus 5-HT neuronal activity.
Eur J Neurosci 16: 817–822.
Spadin, an Antidepressant Sortilin-Derived Peptide
PLoS Biology | www.plosbiology.org 16 April 2010 | Volume 8 | Issue 4 | e1000355
46. Lucas G (2008) Fast-acting antidepressants: are we nearly there? Expert Rev
Neurother 8: 1–3.
47. Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration
increases the expression of cAMP response element binding protein (CREB) in
rat hippocampus. J Neurosci 16: 2365–2372.
48. Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, et al. (2000) cAMP response
element-mediated gene transcription is upregulated by chronic antidepressant
treatment. J Neurosci 20: 4030–4036.
49. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB
mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug
treatments. J Neurosci 15: 7539–7547.
50. Clancy BM, Czech MP (1990) Hexose transport stimulation and membrane
redistribution of glucose transporter isoforms in response to cholera toxin,
dibutyryl cyclic AMP, and insulin in 3T3-L1 adipocytes. J Biol Chem 265:
12434–12443.
51. Sadoul JL, Mazella J, Amar S, Kitabgi P, Vincent JP (1984) Preparation of
neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity
and binding properties on mammalian neurotensin receptors. Biochem Biophys
Res Commun 120: 812–819.
52. Duprat F, Lesage F, Fink M, Reyes R, Heurteaux C, et al. (1997) TASK, a
human background K+ channel to sense external pH variations near
physiological pH. Embo J 16: 5464–5471.
Spadin, an Antidepressant Sortilin-Derived Peptide
PLoS Biology | www.plosbiology.org 17 April 2010 | Volume 8 | Issue 4 | e1000355
